Viking (VKTX) Climbs 10% Following Results from Phase 1 Trial of Dual GLP-1/GIP Receptor Agonist VK2735

Visit StreetInsider.com at http://www.streetinsider.com/Momentum+Movers/Viking+%28VKTX%29+Climbs+10%25+Following+Results+from+Phase+1+Trial+of+Dual+GLP-1GIP+Receptor+Agonist+VK2735/22976946.html for the full story.